Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

SABCS 2024

Breast Cancer

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

CHICAGO 2025

Breast Cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

SABCS 2024

Breast Cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

ESMO 2025

Breast Cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Breast Cancer

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial

JAMA Oncol

Tao Z, Zhang J, Zheng Q, Wang Y, Cai L, Xu H, Xu X, Kong X, Ding S, Hao C, Wang H, Zong H, Jin X, Wang X, Li Y, Yang X, Li W, Du X, Chen H, Wu P, Li P, Mao L, Ding L, Hu X, Wang S

doi: 10.1001/jamaoncol.2025.2092

Related content

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial